This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willems, F. F. Articles by Verheugt, F. W. A. Search for Related Content PubMed PubMed Citation Articles by Willems, F. F. Articles by Verheugt, F. W. A.

Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease

Frank F. Willems, MD^*,*, Wim R. M. Aengevaeren, MD, PhD, Godfried H. J. Boers, MD, PhD, Henk J. Blom, PhD and Freek W. A. Verheugt, MD, PhD, FACC

^* Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands
Heart Center, University Medical Center, Nijmegen, The Netherlands
Department of Internal Medicine, University Medical Center, Nijmegen, The Netherlands
Laboratory of Pediatrics and Neurology, University Medical Center, Nijmegen, The Netherlands

View larger version (20K): [in a new window]   Figure 1 Effect of acetylcholine and nitroglycerin (NTG) on percent change in volumetric coronary blood flow in both groups. Solid diamond = baseline; solid square = follow-up. *p = 0.15 for the difference between baseline and follow-up at maximal dosage of acetylcholine (placebo group). **p < 0.05 for the difference between baseline and follow-up at the maximal dosage of acetylcholine (folic acid/cobalamin group). p < 0.005 for the difference at baseline and follow-up between the placebo group and the folic acid/cobalamin group with the general linear model.

View larger version (18K): [in a new window]   Figure 2 Effect of acetylcholine and nitroglycerin (NTG) on percent change in mean segment diameter (MSD) in both groups. Solid diamond = baseline; solid square = follow-up. *p = 0.09 for the difference between baseline and follow-up at maximal dosage of acetylcholine (placebo group). **p = 0.10 for the difference between baseline and follow-up at the maximal dosage of acetylcholine (folic acid/cobalamin group). p = 0.15 for the difference at baseline and follow-up between the placebo group and the folic acid/cobalamin group with the general linear model.

View larger version (19K): [in a new window]   Figure 3 Effect of acetylcholine and nitroglycerin (NTG) on percent change in minimal obstruction diameter (MOD) in both groups. Solid diamond = baseline; solid square = follow-up. *p = 0.06 for the difference between baseline and follow-up at maximal dosage of acetylcholine (placebo group). **p = 0.26 for the difference between baseline and follow-up at the maximal dosage of acetylcholine (folic acid/cobalamin group). p = 0.14 for the difference at baseline and follow-up between the placebo group and the folic acid/cobalamin group with the general linear model.